These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23629496)

  • 1. Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
    Harrison C
    Nat Rev Drug Discov; 2013 May; 12(5):335. PubMed ID: 23629496
    [No Abstract]   [Full Text] [Related]  

  • 2. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
    Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
    Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
    Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
    Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast: first global approval.
    Poole RM; Ballantyne AD
    Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R; Levin E; Koo J
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
    Kearns DG; Uppal S; Chat VS; Wu JJ
    J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic tearing induced by apremilast.
    Norris MR; Bielory L
    Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
    [No Abstract]   [Full Text] [Related]  

  • 14. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
    Reinke T
    Manag Care; 2017 Oct; 26(10):8-9. PubMed ID: 29068290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis improvement and satisfaction in patients using a clobetasol spray and oral apremilast combination regimen: A pilot study.
    Wei C; Friedman AJ; Prussick RB
    J Am Acad Dermatol; 2020 Oct; 83(4):1198-1200. PubMed ID: 32088274
    [No Abstract]   [Full Text] [Related]  

  • 17. Apremilast as a treatment for psoriasis.
    Shutty B; West C; Pellerin M; Feldman S
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.